Wall Street brokerages expect Ra Pharmaceuticals Inc (NASDAQ:RARX) to report earnings per share of ($0.50) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Ra Pharmaceuticals’ earnings, with estimates ranging from ($0.53) to ($0.44). Ra Pharmaceuticals reported earnings per share of ($0.51) in the same quarter last year, which would indicate a positive year over year growth rate of 2%. The business is expected to issue its next quarterly earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Ra Pharmaceuticals will report full-year earnings of ($1.98) per share for the current year, with EPS estimates ranging from ($2.08) to ($1.81). For the next financial year, analysts anticipate that the company will report earnings of ($2.55) per share, with EPS estimates ranging from ($2.90) to ($2.28). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.03).
Ra Pharmaceuticals stock traded down $0.06 during mid-day trading on Tuesday, reaching $46.19. The company had a trading volume of 63,191 shares, compared to its average volume of 2,218,099. Ra Pharmaceuticals has a 52 week low of $11.27 and a 52 week high of $47.08. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of -22.42 and a beta of 1.34. The company has a quick ratio of 15.30, a current ratio of 15.30 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $30.15 and a 200-day moving average of $27.50.
In related news, insider Ramin Farzaneh-Far sold 10,595 shares of Ra Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.26, for a total transaction of $267,629.70. Following the transaction, the insider now owns 8,521 shares of the company’s stock, valued at approximately $215,240.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alonso Ricardo sold 2,285 shares of Ra Pharmaceuticals stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $46.70, for a total transaction of $106,709.50. Following the transaction, the insider now directly owns 6,858 shares in the company, valued at approximately $320,268.60. The disclosure for this sale can be found here. Insiders sold a total of 43,475 shares of company stock worth $1,402,939 in the last ninety days. Insiders own 4.30% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Prudential Financial Inc. raised its holdings in shares of Ra Pharmaceuticals by 0.5% in the second quarter. Prudential Financial Inc. now owns 120,890 shares of the company’s stock valued at $3,635,000 after purchasing an additional 640 shares during the last quarter. Moody Aldrich Partners LLC increased its holdings in Ra Pharmaceuticals by 2.8% during the second quarter. Moody Aldrich Partners LLC now owns 41,039 shares of the company’s stock worth $1,234,000 after buying an additional 1,134 shares during the last quarter. Virginia Retirement Systems ET AL increased its holdings in Ra Pharmaceuticals by 12.9% during the second quarter. Virginia Retirement Systems ET AL now owns 10,500 shares of the company’s stock worth $316,000 after buying an additional 1,200 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in Ra Pharmaceuticals by 26.2% during the third quarter. Meeder Asset Management Inc. now owns 6,209 shares of the company’s stock worth $147,000 after buying an additional 1,290 shares during the last quarter. Finally, Swiss National Bank increased its holdings in Ra Pharmaceuticals by 3.6% during the second quarter. Swiss National Bank now owns 49,300 shares of the company’s stock worth $1,482,000 after buying an additional 1,700 shares during the last quarter. Hedge funds and other institutional investors own 91.59% of the company’s stock.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Recommended Story: Why is cost of goods sold important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.